Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. It was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA) and the U.S. Food and Drug Administration(FDA).
This product description is for medical and educational purposes only.
They are not intended to promote PR or sales campaigns.
For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.